An observational study in Breast Cancer and Osteoporosis, sponsored by AstraZeneca. Completed at 1 site in Slovenia. Open to female participants aged 55 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-07-03.
Sponsored by AstraZeneca · Observational
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.
This study's planned enrollment of 560 is above the median of 184 across 2,711 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →AstraZeneca is the lead sponsor of 3,492 studies on the registry; 266 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 176 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Institute of Oncology
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
To determine the effect of aromatase inhibitors therapy on bone mineral density as measured by DEXA scan and compare it to the effects of tamoxifen and no hormonal therapy.
Time frame: once
To determine the bone fracture rate in women on aromatase inhibitors therapy and compare it to fracture rates observed in the tamoxifen and the hormone-independent group.
Time frame: once
The record gives a start of Aug 2008 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.